Parallel Advisors’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,940
| Closed | -$22.3K | – | 3863 |
|
|
2025
Q4 | $22.3K | Hold |
4,940
| – | – | ﹤0.01% | 2226 |
|
|
2025
Q3 | $26.6K | Hold |
4,940
| – | – | ﹤0.01% | 2111 |
|
|
2025
Q2 | $26.8K | Buy |
4,940
+472
| +11% | +$1.87K | ﹤0.01% | 2055 |
|
|
2025
Q1 | $12.4K | Buy |
4,468
+355
| +9% | +$1.24K | ﹤0.01% | 2350 |
|
|
2024
Q4 | $14K | Buy |
4,113
+1,810
| +79% | +$5.22K | ﹤0.01% | 2295 |
|
|
2024
Q3 | $6.77K | Sell |
2,303
-593
| -20% | -$1.95K | ﹤0.01% | 2525 |
|
|
2024
Q2 | $9.85K | Buy |
2,896
+2,202
| +317% | +$7.2K | ﹤0.01% | 2321 |
|
|
2024
Q1 | $2.1K | Buy |
+694
| New | +$2.44K | ﹤0.01% | 2812 |
|
|
2023
Q4 | – | Sell |
-664
| Closed | -$4.54K | – | 3355 |
|
|
2023
Q3 | $4.54K | Buy |
664
+23
| +4% | +$203 | ﹤0.01% | 2537 |
|
|
2023
Q2 | $6.68K | Buy |
641
+399
| +165% | +$3.57K | ﹤0.01% | 2327 |
|
|
2023
Q1 | $1.69K | Buy |
+242
| New | +$2.11K | ﹤0.01% | 2821 |
|
|
2022
Q4 | – | Sell |
-112
| Closed | -$1K | – | 3389 |
|
|
2022
Q3 | $1K | Sell |
112
-191
| -63% | -$2.23K | ﹤0.01% | 2875 |
|
|
2022
Q2 | $4K | Sell |
303
-16
| -5% | -$265 | ﹤0.01% | 2327 |
|
|
2022
Q1 | $6K | Buy |
319
+8
| +3% | +$160 | ﹤0.01% | 2220 |
|
|
2021
Q4 | $11K | Buy |
311
+231
| +289% | +$9.29K | ﹤0.01% | 2061 |
|
|
2021
Q3 | $4K | Hold |
80
| – | – | ﹤0.01% | 2441 |
|
|
2021
Q2 | $6K | Buy |
80
+48
| +150% | +$4.8K | ﹤0.01% | 2216 |
|
|
2021
Q1 | $3K | Buy |
+32
| New | +$3.1K | ﹤0.01% | 2352 |
|
Parallel Advisors's CVAC Position: Q1 2026 in Review
Parallel Advisors sold out of CureVac (CVAC) in Q1 2026, closing a stake of 4,940 shares — an estimated $22.3K sold.
Parallel Advisors first reported a position in CVAC in Q1 2021 and held it in 18 quarters. The position peaked at $26.8K in Q2 2025. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- Parallel Advisors reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- Parallel Advisors sold 4,940 CureVac shares in Q1 2026, an estimated $22.3K.
- Parallel Advisors first reported a position in CureVac in Q1 2021 and held it in 18 quarters.
- Parallel Advisors's CureVac position peaked at $26.8K in Q2 2025.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.